Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT05960955
- Locations
- 🇨🇳
Tianjin Provincial Tumor Hospital, Tianjin, China
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: AK127 in combination with AK112
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 216
- Registration Number
- NCT05951608
AK104 for Recurrent or Metastatic Vulvar Cancer
- Conditions
- Vulvar Cancer
- Interventions
- Drug: AK104+ Paclitaxel+Cisplatin or Carboplatin
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 20
- Registration Number
- NCT05932212
- Locations
- 🇨🇳
Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yant-Sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiangzhuang, Hebei, China
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Advanced Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 233
- Registration Number
- NCT05904379
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 205
- Registration Number
- NCT05868876
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Akeso
- Target Recruit Count
- 78
- Registration Number
- NCT05859750
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan, Hubei, China
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 170
- Registration Number
- NCT05846867
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, China
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- Conditions
- Advanced Squamous Non Small Cell Lung Cancer
- Interventions
- Drug: AK112, Carboplatin, PaxlitaxelDrug: Tislelizumab, Carboplatin, Paxlitaxel
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 532
- Registration Number
- NCT05840016
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Akeso
- Target Recruit Count
- 87
- Registration Number
- NCT05689853
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of AK130 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 19
- Registration Number
- NCT05653284
- Locations
- 🇨🇳
The Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China